People Background Check
Find People:

James J Stec, Age 536 Sleepy Hollow Dr, Plymouth, MA 02360

Get Report
Known as:
James Abbott Jamesj Stec

James Stec Phones & Addresses

6 Sleepy Hollow Dr, Plymouth, MA 02360 (508) 224-7173

Belmont, NH

Hartford, VT

385 Quechee Hartland Rd, White River Junction, VT 05001 (802) 291-7147

146 Kendrick Ave, Quincy, MA 02169 (617) 786-0917

75 Palmer St, Quincy, MA 02169 (617) 770-1558

Holbrook, MA

Show more

Social networks

James J Stec

Linkedin

Work

Company: Immunogen, inc. Feb 2019 Position: Executive director medical affair

Education

School / High School: Harvard University 1998 to 2007 Specialities: Biology

Skills

Clinical Development • Clinical Research • Oncology • Pharmaceutical Industry • Biotechnology • Clinical Trials • Medical Affairs • Drug Development • Gcp • Ctms • Cro • Hematology • Life Sciences • Regulatory Affairs • Immunology • Therapeutic Areas • Pharmacovigilance • Medical Writing • Pharmacology • Lifesciences • Cancer • Infectious Diseases • Drug Discovery • Neurology • Vaccines • Clinical Monitoring • Pharmaceuticals

Industries

Pharmaceuticals

Mentions for James J Stec

James Stec resumes & CV records

Resumes

James Stec Photo 14

Executive Director Medical Affair

Location:
Plymouth, MA
Industry:
Pharmaceuticals
Work:
Immunogen, Inc.
Executive Director Medical Affair Immunogen, Inc.
Executive Director Medical Affairs Immunogen, Inc.
Director Scientific Affairs Aveo Oncology Nov 2010 - Sep 2012
Director of Medical Affairs Ipi Apr 2009 - Nov 2010
Senior Medical Science Liaison Synta Pharmaceuticals 2009 - 2009
Medical Science Liaison Abbott Oncology 2005 - 2009
Clinical Science Manager Praecis 2004 - 2005
Msl Takeda Oncology 2000 - 2004
Senior Manager
Education:
Harvard University 1998 - 2007
Plymouth State University 1989 - 1993
Bachelors, Bachelor of Science, Biology
Skills:
Clinical Development, Clinical Research, Oncology, Pharmaceutical Industry, Biotechnology, Clinical Trials, Medical Affairs, Drug Development, Gcp, Ctms, Cro, Hematology, Life Sciences, Regulatory Affairs, Immunology, Therapeutic Areas, Pharmacovigilance, Medical Writing, Pharmacology, Lifesciences, Cancer, Infectious Diseases, Drug Discovery, Neurology, Vaccines, Clinical Monitoring, Pharmaceuticals

Publications & IP owners

Us Patents

Multigene Predictors Of Response To Chemotherapy

US Patent:
2005026, Dec 1, 2005
Filed:
Sep 30, 2004
Appl. No.:
10/955054
Inventors:
Lajos Pusztai - Pearland TX, US
W. Symmans - Houston TX, US
Kenneth Hess - Houston TX, US
Mark Ayers - Pennington NJ, US
James Stec - Plymouth MA, US
International Classification:
C12Q001/68
G06F019/00
G01N033/48
G01N033/50
US Classification:
435006000, 702019000, 702020000
Abstract:
The present invention provides the identification of genes that are expressed in tumors that are responsive to a given therapeutic agent and whose expression (either increased expression or decreased expression) correlates with responsiveness to that therapeutic agent. One or more of the genes of the present invention can be used as markers (or surrogate markers) to identify tumors that are likely to be successfully treated by that agent.

Novel Compositions And Methods For The Identification, Assessment, Prevention And Therapy Of Ovarian Cancer

US Patent:
2003018, Sep 25, 2003
Filed:
Feb 7, 2003
Appl. No.:
10/361112
Inventors:
Andrew Damokosh - West Hartford CT, US
Natalia Iartchouk - Wayland MA, US
James Stec - Plymouth MA, US
Edwin Clark - Ashland MA, US
Karen Lu - Houston TX, US
Lynn Hartmann - Rochester MN, US
Assignee:
Millennium Pharmaceuticals, Inc.
International Classification:
C12Q001/68
G01N033/574
A61K033/24
A61K031/337
US Classification:
435/006000, 435/007230, 514/449000, 424/649000
Abstract:
The present invention is directed to the identification of markers that can be used to determine whether ovarian cancer is sensitive or resistant to a therapeutic agent. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with sensitivity or resistance to a therapeutic agent. Thus, by examining the expression of the individual markers of a marker set, also referred to as the expression profile of the marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of the ovarian cancer.

Possible Relatives

Dawn M Stec  Deborah A Stec  Eddie L Stec  Edward C Stec  Frank I Stec  Jason G Stec  John M Stec  James M Last  James G Stanco  James A Stanczak 

NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.